Literature DB >> 7835343

Novel mechanism and factor for regulation by HIV-1 Tat.

Q Zhou1, P A Sharp.   

Abstract

Tat regulation of human immunodeficiency virus (HIV) transcription is unique because of its specificity for an RNA target, TAR, and its ability to increase the efficiency of elongation by polymerase. A reconstituted reaction that is Tat-specific and TAR-dependent for activation of HIV transcription has been used to identify and partially purify a cellular activity that is required for trans-activation by Tat, but not by other activators. In the reaction, Tat stimulates the efficiency of elongation by polymerase, whereas Sp1 and other DNA sequence-specific transcription factors activate the rate of initiation. Furthermore, while TATA binding protein (TBP)-associated factors (TAFs) in the TFIID complex are required for activation by transcription factors, they are dispensable for Tat function. Thus, Tat acts through a novel mechanism, which is mediated by a specific host cellular factor, to stimulate HIV-1 gene expression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7835343      PMCID: PMC398086          DOI: 10.1002/j.1460-2075.1995.tb07006.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  39 in total

1.  Two distinct nuclear transcription factors recognize loop and bulge residues of the HIV-1 TAR RNA hairpin.

Authors:  C T Sheline; L H Milocco; K A Jones
Journal:  Genes Dev       Date:  1991-12       Impact factor: 11.361

2.  tat regulates binding of the human immunodeficiency virus trans-activating region RNA loop-binding protein TRP-185.

Authors:  F Wu; J Garcia; D Sigman; R Gaynor
Journal:  Genes Dev       Date:  1991-11       Impact factor: 11.361

Review 3.  The complexities of eukaryotic transcription initiation: regulation of preinitiation complex assembly.

Authors:  R G Roeder
Journal:  Trends Biochem Sci       Date:  1991-11       Impact factor: 13.807

4.  Functional roles for the TATA promoter and enhancers in basal and Tat-induced expression of the human immunodeficiency virus type 1 long terminal repeat.

Authors:  B Berkhout; K T Jeang
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

5.  Transcriptional elongation by RNA polymerase II is stimulated by transactivators.

Authors:  K Yankulov; J Blau; T Purton; S Roberts; D L Bentley
Journal:  Cell       Date:  1994-06-03       Impact factor: 41.582

6.  Promoter specificity of basal transcription factors.

Authors:  J D Parvin; H T Timmers; P A Sharp
Journal:  Cell       Date:  1992-03-20       Impact factor: 41.582

7.  Isolation of coactivators associated with the TATA-binding protein that mediate transcriptional activation.

Authors:  B D Dynlacht; T Hoey; R Tjian
Journal:  Cell       Date:  1991-08-09       Impact factor: 41.582

8.  The HIV-1 Tat protein activates transcription from an upstream DNA-binding site: implications for Tat function.

Authors:  C D Southgate; M R Green
Journal:  Genes Dev       Date:  1991-12       Impact factor: 11.361

9.  Coactivators for a proline-rich activator purified from the multisubunit human TFIID complex.

Authors:  N Tanese; B F Pugh; R Tjian
Journal:  Genes Dev       Date:  1991-12       Impact factor: 11.361

10.  HIV-1 Tat protein promotes formation of more-processive elongation complexes.

Authors:  R A Marciniak; P A Sharp
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

View more
  60 in total

1.  Transcriptional activation by artificial recruitment in mammalian cells.

Authors:  J Nevado; L Gaudreau; M Adam; M Ptashne
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

2.  Spt5 cooperates with human immunodeficiency virus type 1 Tat by preventing premature RNA release at terminator sequences.

Authors:  Cyril F Bourgeois; Young Kyeung Kim; Mark J Churcher; Michelle J West; Jonathan Karn
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

3.  Transcription-coupled and DNA damage-dependent ubiquitination of RNA polymerase II in vitro.

Authors:  Keng-Boon Lee; Dong Wang; Stephen J Lippard; Phillip A Sharp
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

4.  Ubiquitination of RNA polymerase II large subunit signaled by phosphorylation of carboxyl-terminal domain.

Authors:  A Mitsui; P A Sharp
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

5.  Identification of Tat-SF1 cellular targets by exon array analysis reveals dual roles in transcription and splicing.

Authors:  Heather B Miller; Timothy J Robinson; Raluca Gordân; Alexander J Hartemink; Mariano A Garcia-Blanco
Journal:  RNA       Date:  2011-01-31       Impact factor: 4.942

6.  Transfer of Tat and release of TAR RNA during the activation of the human immunodeficiency virus type-1 transcription elongation complex.

Authors:  N J Keen; M J Churcher; J Karn
Journal:  EMBO J       Date:  1997-09-01       Impact factor: 11.598

7.  CA150, a nuclear protein associated with the RNA polymerase II holoenzyme, is involved in Tat-activated human immunodeficiency virus type 1 transcription.

Authors:  C Suñé; T Hayashi; Y Liu; W S Lane; R A Young; M A Garcia-Blanco
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

8.  A human primary T-lymphocyte-derived human immunodeficiency virus type 1 Tat-associated kinase phosphorylates the C-terminal domain of RNA polymerase II and induces CAK activity.

Authors:  S Nekhai; R R Shukla; A Kumar
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

9.  HIV-1 Tat and host AFF4 recruit two transcription elongation factors into a bifunctional complex for coordinated activation of HIV-1 transcription.

Authors:  Nanhai He; Min Liu; Joanne Hsu; Yuhua Xue; Seemay Chou; Alma Burlingame; Nevan J Krogan; Tom Alber; Qiang Zhou
Journal:  Mol Cell       Date:  2010-05-14       Impact factor: 17.970

10.  Rabbit cells expressing human CD4 and human CCR5 are highly permissive for human immunodeficiency virus type 1 infection.

Authors:  R F Speck; M L Penn; J Wimmer; U Esser; B F Hague; T J Kindt; R E Atchison; M A Goldsmith
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.